Share on LinkedInShare on LinkedIn

ARTICLE · 08 DECEMBER 2021

IPR Waiver And Covid-19 Vaccines

Khurana & Khurana, Advocates and IP Attorneys
Explore more from Khurana & Khurana, Advocates and IP Attorneys

December of 2019, this is when the outbreak of novel coronavirus disease (COVID-19) was initially noticed in a seafood market of Wuhan city in Hubei Province of China.

IndiaIntellectual Property
Vishwas Nagori
Vishwas Nagori
Vaishnavi Deshpande
Vaishnavi Deshpande
Author LinkedIn connections

December of 2019, this is when the outbreak of novel coronavirus disease (COVID-19) was initially noticed in a seafood market of Wuhan city in Hubei Province of China. On March 11, 2020 World Health Organisation declared COVID-19 as a pandemic and that's when the things changed. Every country was in the race of developing a vaccine for this disease and certain high-income nations came up with a vaccine too, but their ability to fight the disease or what we call their effectiveness was always questioned. Before it all became a mere business, in October of 2020, India and South Africa took the initiative and requested the World Trade Organisation (WTO) to suspend the intellectual property rights related to COVID-19 vaccine for a limited period of time. The countries had asked the TRIPS Council to recommend, a waiver on the implementation, application and enforcement of four sections in the second part of the agreement. These sections are "1, 4, 5, and 7". They pertain

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from